IBRX Stock Down -20% after 5-Day Loss Streak
ImmunityBio (IBRX) stock hit day 5 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -20% return. The company has lost about $399 Mil in value over the last 5 days, with its current market capitalization at about $2.0 Bil. The stock remains 11.7% below its value at the end of 2024. This compares with year-to-date returns of 8.7% for the S&P 500.
IBRX is a clinical-stage biotechnology company providing immunotherapy, cell therapy, and vaccine platforms to treat cancers and infectious diseases, with therapies in advanced clinical trials. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell IBRX.
Comparing IBRX Stock Returns With The S&P 500
The following table summarizes the return for IBRX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | IBRX | S&P 500 |
|---|---|---|
| 1D | -0.9% | -0.2% |
| 5D (Current Streak) | -19.9% | -1.1% |
| 1M (21D) | -16.6% | 1.4% |
| 3M (63D) | -22.1% | 7.7% |
| YTD 2025 | -11.7% | 8.7% |
| 2024 | -49.0% | 23.3% |
| 2023 | -1.0% | 24.2% |
| 2022 | -16.6% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: IBRX Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 66 S&P constituents with 3 days or more of consecutive gains and 22 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 42 | 7 |
| 4D | 14 | 3 |
| 5D | 3 | 10 |
| 6D | 2 | 2 |
| 7D or more | 5 | 0 |
| Total >=3 D | 66 | 22 |
Key Financials for ImmunityBio (IBRX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0.6 Mil | $14.7 Mil |
| Operating Income | $-361.4 Mil | $-344.2 Mil |
| Net Income | $-583.2 Mil | $-413.6 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $16.5 Mil | $26.4 Mil |
| Operating Income | $-64.4 Mil | $-71.3 Mil |
| Net Income | $-129.6 Mil | $-92.6 Mil |
The losing streak IBRX stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.